相关实验视频

Updated: Jun 12, 2025

SDS-PAGE/Immunoblot Detection of Aβ Multimers in Human Cortical Tissue Homogenates using Antigen-Epitope Retrieval

SDS-PAGE/Immunoblot Detection of Aβ Multimers in Human Cortical Tissue Homogenates using Antigen-Epitope Retrieval

Published on: April 23, 2010

解开阿尔茨海默氏症的复杂性,具有独特的Aβ₄₂纤维类型和特定的AV-45结合

Qinyue Zhao^1,2, Youqi Tao^1,2, Yuxuan Yao^1,2

¹Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.

Nature chemical biology

|June 10, 2025

概括

阿尔茨海默病的研究揭示了第三种类型的粉样β 42 (Aβ42) 纤维在AD大脑的可溶性部分. 这一发现突显了阿尔茨海默病患者中发现的Aβ42蛋白聚合物的显著结构多样性.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
结构生物学结构生物学

背景情况:

粉样β蛋白 (1-42) (Aβ42) 的异常聚合是阿尔茨海默病 (AD) 的标志.
在此之前,在AD大脑组织的不溶性部分中发现了两种主要类型的Aβ42纤维素.
据认为"可溶性"部分含有较少或不含有粉样纤维.

研究的目的:

为了研究AD脑组织的可溶和不可溶分数中的Aβ42聚合物的结构特征.
为了识别Aβ42纤维的新型结构多态.
为了检查Aβ42纤维与正子发射断层扫描 (PET) 标记物的相互作用.

主要方法:

从AD脑组织中提取sarkosyl,以分离可溶和不能溶的分量.
低温电子显微镜 (cryo-EM) 用于Aβ42纤维的高分辨率结构分析.
用PET追踪器AV-45对Aβ42纤维进行复合,用于结构研究.

主要成果:

在以前"可溶"的部分中发现了粉样纤维,与不溶性纤维相比,它们的捆绑较松.
在一个AD大脑的可溶性部分中发现了Aβ42纤维的新型第三种 (类型III).
低温电磁波检测显示,在I型Aβ42纤维素中存在一个联体结合通道,但在III型纤维素中没有,AV-45在I型纤维素中垂直结合.

结论:

这项研究揭示了阿尔茨海默病中ex vivo Aβ42纤维的显著结构异质性.
存在第三种Aβ42纤维多态 (III型),在可溶性分数中发现.
Aβ42纤维的结构差异可能会影响它们与AV-45.5等诊断标记物的相互作用.

更多相关视频

Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain

Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain

Published on: October 24, 2017

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

相关概念视频

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...